Shares of Merus (NASDAQ:MRUS - Get Free Report) have been given a consensus recommendation of "Buy" by the thirteen ratings firms that are covering the company, Marketbeat.com reports. Eleven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $86.70.
Several analysts have issued reports on the company. Lifesci Capital raised Merus to a "strong-buy" rating in a research note on Monday, July 29th. UBS Group assumed coverage on shares of Merus in a research note on Thursday, October 24th. They issued a "buy" rating and a $72.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $85.00 price objective on shares of Merus in a research note on Friday, November 1st. Canaccord Genuity Group reiterated a "buy" rating and issued a $67.00 price objective on shares of Merus in a report on Thursday, July 25th. Finally, HC Wainwright restated a "buy" rating and set a $85.00 target price on shares of Merus in a report on Friday, November 1st.
View Our Latest Analysis on MRUS
Merus Price Performance
MRUS stock remained flat at $54.50 during mid-day trading on Friday. The company's stock had a trading volume of 340,271 shares, compared to its average volume of 386,963. The firm's 50 day simple moving average is $50.99 and its two-hundred day simple moving average is $51.66. Merus has a 52-week low of $22.01 and a 52-week high of $61.61.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new stake in shares of Merus during the third quarter valued at approximately $675,000. State of New Jersey Common Pension Fund D purchased a new position in Merus during the third quarter valued at $1,870,000. TimesSquare Capital Management LLC lifted its position in Merus by 49.5% during the third quarter. TimesSquare Capital Management LLC now owns 272,435 shares of the biotechnology company's stock valued at $13,611,000 after buying an additional 90,215 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of Merus during the 3rd quarter valued at $2,113,000. Finally, US Bancorp DE purchased a new stake in shares of Merus in the 3rd quarter worth about $103,000. Hedge funds and other institutional investors own 96.14% of the company's stock.
About Merus
(
Get Free ReportMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
